Clinical trial NCT07506395 page content retrieval error

ClinicalTrials.gov, operated by the National Library of Medicine, reported that page content for clinical trial NCT07506395 could not be fully retrieved. This is a system-level notification indicating incomplete data retrieval rather than a regulatory document or enforcement action.

HER2 trial, trastuzumab serplulimab, biliary urothelial cancer

National Cancer Institute registered a Phase 2 clinical trial (NCT07506057) on ClinicalTrials.gov evaluating trastuzumab combined with serplulimab for HER2-positive biliary urothelial cancer. The study is sponsored by National Cancer Institute investigators and will assess safety and efficacy of this novel combination therapy in approximately 40 patients.

Ofatumumab Multiple Sclerosis Real-World Experience Study

NIH National Library of Medicine registered a new observational study on ClinicalTrials.gov examining real-world use of ofatumumab in multiple sclerosis patients. The study (NCT07504783) will collect data on treatment outcomes and patient experiences outside controlled clinical trial settings. Trial sponsors must register qualifying clinical trials on ClinicalTrials.gov under FDAAA 801 requirements.

Transcranial alternating current stimulation frontotemporal dementia trial, Italy

ClinicalTrials.gov registered a new interventional study (NCT07505784) evaluating transcranial alternating current stimulation (tACS) for frontotemporal dementia. The single-center trial is conducted in Italy. Registration was posted to the public ClinicalTrials.gov registry.

Sinovac Phase III meningococcal vaccine trial, children 12-23 months

Sinovac Phase III meningococcal vaccine trial, children 12-23 months

Distributed Encrypted Data System with Hash Verification

The European Patent Office published Patent EP4179693A1, filed by International Business Machines Corporation, covering a method and system for distributing encrypted data objects with hash verification. The invention enables verification of data integrity during encrypted data transmission. The patent application was published March 25, 2026.

Cytisine liquid pharmaceutical composition patent

The European Patent Office published EP4072517A1 on March 25, 2026, a patent application by Adamed Pharma S.A. covering a liquid pharmaceutical composition comprising cytisine. The inventors are Kubiak, Rzasa, Zarzycka, and Garbera. The patent is designated across 38 European states.

Nestlé RECOVER Dietary Supplement Patent - Therapeutic Applications

The European Patent Office published Patent EP3976088A1 for Nestlé S.A.'s RECOVER dietary supplement. The patent covers compositions including vitamins, minerals, and amino acids for therapeutic applications, particularly muscle function support (A61P 21/00). The patent is designated for all 31 European member states and extension countries.

Antimicrobial Agents and Compositions Patent

European Patent Office published patent application EP4031128A1 for Koda Therapeutics LLC, covering antimicrobial agents and compositions and uses thereof. The patent application lists three inventors and contains IPC classifications related to pharmaceutical compounds. Designated states include all EPC contracting states across Europe.

Carboplatin Complex Pharmaceutical Patent

The European Patent Office published application EP4006043A1 for a carboplatin complex pharmaceutical compound developed by Advanchl Biotechnology Service Center (Shanghai). The patent application covers the carboplatin complex and pharmaceutical preparations thereof, with inventors including ZHENG, Jianqiang. The application has been published with designated states covering the majority of European countries.